Acceleration Therapeutics, a Division of Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU) announced that laboratory research showed that its AT-101 device effectively treats the narrowed airways and inflammation associated with experimental asthma. Another research study found that a modified AT-101 as a stand alone CPR device was superior to closed chest cardiac compression in terms of post-resuscitation cardiac function despite significantly less myocardial blood flow during CPR with the AT-101.
